Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / SPPI - Spectrum announces resubmitted Eflapegrastim BLA accepted for filing


SPPI - Spectrum announces resubmitted Eflapegrastim BLA accepted for filing

Spectrum Pharmaceuticals (NASDAQ:SPPI) has announced that the resubmitted Biologics License Application for Eflapegrastim has been accepted for filing. The U.S. FDA has set a Prescription Drug User Fee Act goal date of Sept. 9, 2022. “The acceptance of the BLA resubmission is an important incremental step forward in the regulatory review process,” said Tom Riga, President and CEO of Spectrum Pharmaceuticals. SPPI +7.02% premarket to $1.22.

For further details see:

Spectrum announces resubmitted Eflapegrastim BLA accepted for filing
Stock Information

Company Name: Spectrum Pharmaceuticals Inc.
Stock Symbol: SPPI
Market: NASDAQ
Website: sppirx.com

Menu

SPPI SPPI Quote SPPI Short SPPI News SPPI Articles SPPI Message Board
Get SPPI Alerts

News, Short Squeeze, Breakout and More Instantly...